Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Gross Margin (2016 - 2026)

Collegium Pharmaceutical has reported Gross Margin over the past 10 years, most recently at 62.49% for Q4 2025.

  • For Q4 2025, Gross Margin rose 847.0% year-over-year to 62.49%; the TTM value through Dec 2025 reached 59.35%, down 1925.0%, while the annual FY2025 figure was 59.35%, 41.0% down from the prior year.
  • Gross Margin for Q4 2025 was 62.49% at Collegium Pharmaceutical, up from 61.7% in the prior quarter.
  • Over five years, Gross Margin peaked at 1334.14% in Q1 2022 and troughed at 3.48% in Q4 2021.
  • A 5-year average of 175.11% and a median of 58.62% in 2021 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: skyrocketed 127076bps in 2022 and later tumbled -128067bps in 2023.
  • Year by year, Gross Margin stood at 3.48% in 2021, then surged by 1204bps to 38.41% in 2022, then soared by 65bps to 63.19% in 2023, then dropped by -15bps to 54.02% in 2024, then rose by 16bps to 62.49% in 2025.
  • Business Quant data shows Gross Margin for COLL at 62.49% in Q4 2025, 61.7% in Q3 2025, and 57.65% in Q2 2025.